Products & ReviewDrug discovery > Pre-Clinical Development
Syngeneic Models
Accelerate the development of your immuno-oncology drugs with Crown Bioscience’s large panel of immunocompetent syngeneic models.
Request Pricing
Receive your quote directly from the manufacturer.
Purpose: These models offer the immune functionality needed to evaluate efficacy, mechanism of action, and combination strategies for today’s most innovative immunotherapies.
Features or Benefits:
- Full checkpoint inhibitor benchmarking and baseline immune profiling
- Bioluminescent orthotopic and metastatic models for real-time tracking
- Full access to MuBase®, our searchable syngeneic model database
- RNA-seq and NGS data with mutational and transcriptomic insights
- Microbiome analysis tools to assess therapy responders vs. non-responders
- Combination therapy testing, including with ICD inducers and chemotherapy
- Immune cell profiling via validated FACS and IHC platforms
- Confident model selection using curated immuno-profiling, efficacy, and genetic data
- Faster study design and execution with pre-profiled, readily available models
- Predict clinical outcomes by mirroring immune response variability and resistance
Applications:
- Evaluate checkpoint inhibitors (anti-PD-1, PD-L1, CTLA-4) and combination strategies
- Study vaccine, bacterial, and viral immunotherapies
- Model tumor-immune interactions in subcutaneous, orthotopic, and metastatic settings
- Use for biomarker discovery, immunomodulatory profiling, and T cell infiltration studies
- Fast-track IO candidates with large-scale in vivo screening
- Explore microbiome–therapy interactions using fecal sequencing and analysisry, and mechanism-of-action studies
